FORWARD II ASCO Abstract | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website

  • Investor Village needs your help. We are working hard to improve your user experience
    by upgrading the site so it works better on the latest mobile devices, browsers, O/S, etc. Because costs exceed our normal operating budget, we are asking everyone, including "lurkers," to support our efforts.

    Click this PayPal link to make a one-time contribution in whatever amount you think is fair.

    Or click here to support us with a monthly contribution, starting as low as $2.50 per month.

    Payments can be made directly via PayPal or Credit Card with no need to create an Investor Village account. Cancel any time.

IMGN   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  49454 of 49886  at  5/15/2019 6:08:30 PM  by


 In response to msg 49452 by  Bibliobiftek
view thread


Correct me if I am wrong but the data in this abstract for the subset analysis of pts (n = 16) who were bevacizumab-na´ve, had 1-2 prior therapies is identical to the data present in May2018.

Are these different patients? Strange to have the same exact outcome.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 240
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
49458 Re: FORWARD II ASCO Abstract Bibliobiftek 2 5/15/2019 8:53:10 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by